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Abstract
Background: Low dose aspirin (LDA) is an effective strategy to reduce preterm birth. However, LDA might have dif‑
ferential effects globally, based on the etiology of preterm birth. In some regions, malaria in pregnancy could be an
important modifier of LDA on birth outcomes and anemia.
Methods: This is a sub-study of the ASPIRIN trial, a multi-national, randomized, placebo controlled trial evaluating
LDA effect on preterm birth. We enrolled a convenience sample of women in the ASPIRIN trial from the Democratic
Republic of Congo (DRC), Kenya and Zambia. We used quantitative polymerase chain reaction to detect malaria. We
calculated crude prevalence proportion ratios (PRs) for LDA by malaria for outcomes, and regression modelling to
evaluate effect measure modification. We evaluated hemoglobin in late pregnancy based on malaria infection in early
pregnancy.
Results: One thousand four hundred forty-six women were analyzed, with a malaria prevalence of 63% in the DRC
site, 38% in the Kenya site, and 6% in the Zambia site. Preterm birth occurred in 83 (LDA) and 90 (placebo) women,
(PR 0.92, 95% CI 0.70, 1.22), without interaction between LDA and malaria (p = 0.75). Perinatal mortality occurred in
41 (LDA) and 43 (placebo) pregnancies, (PR 0.95, 95% CI 0.63, 1.44), with an interaction between malaria and LDA
(p = 0.014). Hemoglobin was similar by malaria and LDA status.
Conclusions: Malaria in early pregnancy did not modify the effects of LDA on preterm birth, but modified the effect
of LDA on perinatal mortality. This effect measure modification deserves continued study as LDA is used in malaria
endemic regions.
Keywords: Malaria, Pregnancy, Premature birth, Perinatal mortality
Background
Preterm birth is a major cause of neonatal mortality,
and infants born in low- and middle-income countries
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(LMICs) are particularly vulnerable. Recent trials demonstrate that low dose aspirin (LDA) is an effective strategy
to reduce preterm birth [1–3]. However, LDA might have
differential effects in global regions, based on the etiology
of preterm birth. The Eunice Kennedy Shriver National
Institute for Child Health and Human Development
(NICHD) Global Network for Women’s and Children’s
Health Research (GN) recently completed the ASPIRIN
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trial, a multi-country trial of the effects of LDA on preterm birth [3, 4]. While, this study was not powered to
investigate efficacy in individual sites, site-specific data
did not demonstrate a reduction in the risk of preterm
birth for LDA in the Democratic Republic of the Congo
(DRC) [3]. One feature that distinguished this site from
others in the ASPIRIN trial was high malaria prevalence.
Malaria infections during pregnancy are an important
cause of preterm birth in many LMICs, especially subSaharan African countries where malaria infection in
pregnancy is common [5]. Malaria is associated with up
to 36% of all preterm or low birth weight (LBW) infants
born in malaria endemic areas [6]. Malaria treatment or
prophylaxis in the latter half of pregnancy improves outcomes [7]. Studies also suggest that malaria may exert
deleterious effects early in pregnancy that lead to preterm birth, stillbirth, pregnancy loss, anemia or other
adverse pregnancy outcomes [7–9]. Malaria infections
during early pregnancy are associated with abnormal
development of the placental circulation that may result
in hypertensive disorders, intrauterine growth restriction
(IUGR) and prematurity [5]. Early malaria infections may
cause both local and systemic inflammation leading to
poor placentation that leads to these adverse pregnancy
outcomes.
LDA is thought to reduce inflammation and thrombosis that leads to placental dysfunction, preterm birth,
preeclampsia and IUGR [10, 11]. Malaria could be an
important effect modifier of the relationship between
LDA and preterm birth in malaria-endemic regions. For
example, malaria may reduce the beneficial effects of
LDA by increasing inflammation. Conversely, LDA may
reduce the adverse impact of malaria in early pregnancy
by reducing placental inflammation caused by malaria.
LDA treatment to prevent preterm birth has important public health implications, and might be adopted
in LMICs, including those countries in malaria-endemic
regions. Therefore, there is an urgent need to understand
the relationships between LDA and malaria in early pregnancy on maternal and neonatal health. The objectives
of this paper were to investigate if LDA has a differential effect in areas where malaria is prevalent and determine whether malaria infection interacts with the effects
of LDA on pregnancy outcomes. Furthermore, we also
investigated the relationships between malaria, LDA and
anemia in pregnancy to determine if a potential effect of
malaria was mediated through anemia, a common morbidity of the disease.

Methods
This study was a sub-study of the ASPIRIN (Aspirin
Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas) trial [4]. The ASPIRIN trial was a
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multi-national, randomized, double-masked, placebo
controlled trial to evaluate the effects of LDA (81 mg
daily) in nulliparous women on the outcome of preterm
birth (birth before 37 weeks gestational age). Across 8
research sites in LMICs, women were randomized in
a 1:1 ratio to receive LDA (treatment) or an identicallyappearing placebo (control).
Pregnant women were eligible for the ASPIRIN trial if
they were nulliparous, between 14–40 years of age, had
pregnancies characterized by a gestational age between
6 weeks and 0 days and 13 weeks and 6 days (confirmed
by ultrasound), blood pressure < 140/90 mmHg, hemoglobin > 7.0 g/dL, a live singleton fetus, and absence of
fetal anomaly. Women were excluded who had allergy or
contraindication to aspirin, previous aspirin use for more
than 7 days, a history of ≥ 2 first-trimester losses, or the
presence of diabetes or hypertension [4].
For the sub-study, we enrolled a convenience sample of
women participating in the ASPIRIN trial from 4 of the 8
GN sites. The four sites were chosen based on the potential for malaria affecting the pregnancies in the study
regions, and represented a range of malaria endemicity
(high and low). These 4 sites were located in the DRC
(North and South Ubangi Provinces), Kenya (Western
region), Pakistan (near the city of Karachi), and Zambia
(south and east of the capital city of Lusaka).
Women enrolled in the malaria sub-study had blood
collected at times coincident with blood collection in
the ASPIRIN trial. Blood was collected at enrollment
(6–13 6/7 weeks gestation) and during the third trimester
(between 26–30 weeks gestation), using dried blood spot
techniques. All blood spot cards were shipped to a central
laboratory, the Meshnick Laboratory at the University of
North Carolina (U.S.) for analyses. The PCR results were
performed in batches, in most cases, after the conclusion of pregnancies, therefore the PCR research results
were not available to guide treatment decisions during
pregnancy. Rapid diagnostic tests (RDTs) were also performed for women enrolled at the Pakistan, Zambia and
Kenya sites, and women were treated according to local
standards based on the results. No RDTs were performed
at the DRC site. Each sample was tested in duplicate for
P. falciparum lactate dehydrogenase (pfldh) by quantitative polymerase chain reaction (qPCR). Because malaria
parasites were not detected in the samples from Pakistan, the women enrolled from the Pakistani site were
excluded from subsequent analyses.
We defined primary and secondary efficacy outcomes
as specified in the ASPIRIN trial. Therefore, preterm
delivery was defined as delivery after 20 weeks, but
before 37 0/7 weeks gestation. We defined hypertensive
disorders to include pre-eclampsia, eclampsia, and gestational hypertension. We defined small for gestational age

Bauserman et al. BMC Pregnancy and Childbirth

(2022) 22:303

as a birth weight less than 10% of the INTERGROWTH21st growth standard.[12] We defined perinatal mortality as stillbirths and deaths in the perinatal period from
20 weeks gestation to 7 days post-partum. Additionally,
we used a priori specifications for other maternal outcomes of interest, such as maternal vaginal bleeding,
antepartum/postpartum hemorrhage, maternal mortality and a combined category of preterm and hypertensive disorders. We used a priori defined specifications for
other fetal outcomes of interest, including preterm delivery < 34 weeks, birthweight < 2500 g, birthweight < 1500 g
and stillbirth. We also defined malaria in late pregnancy
as an infection in women for whom we collected a secondary blood sample between 26–30 weeks that was positive for malaria by qPCR.
We performed descriptive statistics for bivariate comparisons. Crude prevalence proportion ratios (PRs) were
calculated for LDA treatment by P. falciparum infection in the first trimester by each variable using stratified tables for all sites and for each site individually. We
chose to present prevalence proportion ratios instead
of incidence ratios since our enrollment occurred after
conception, and therefore true incidence of adverse pregnancy outcomes (outcomes from conception to end of
pregnancy) could not be accurately determined. Poisson models were developed to evaluate effect measure
modification of malaria on the effect of LDA in regards
to maternal and fetal outcomes of interest with terms
included for treatment, malaria in the first trimester, site,
and the interaction term of malaria in the first trimester
and LDA treatment. Similar models were constructed
separately for each site to estimate the prevalence ratio
of preterm birth and perinatal mortality with terms
included for treatment, malaria in the first trimester, and
the interaction term of malaria in the first trimester and
LDA treatment.
We used prevalence ratios (PRs) to investigate the relationship between early pregnancy malaria status and late
pregnancy hemoglobin levels. Hemoglobin levels were
measured by point of care testing devices in the third
trimester (between 26–30 weeks). We used multiple cutoffs for hemoglobin levels (≤ 8 g/dL, ≤ 9 g/dL, ≤ 10 g/dL,
and ≤ 11 g/dL) to assess whether malaria in the first trimester was an effect measure modifier for the relationship between LDA treatment and hemoglobin levels in
late pregnancy. Comparisons were limited to observations without missing data for each variable. All analyses
were performed using the R statistical platform (version 4.0.2) and SAS version 9.4 (SAS Institute, Cary, NC,
USA).
This study was approved by the relevant ethics committees at the institutions conducting the study at each site
prior to the initiation of study activities. The study was
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also approved by the ethics committees at the partner
U.S.-based institutions (University of North Carolina at
Chapel Hill, Columbia University, University of Alabama
at Birmingham and Indiana University) and by RTI International, the data coordinating center. All women provided informed consent prior to their participation in the
sub-study. The ASPIRIN trial was registered in clinicaltrials.gov (NCT02409680).

Results
We included 1,446 pregnant women in our analyses; 469
(32%) from DRC, 642 (44%) from Kenya, and 335 (23%)
from Zambia (Fig. 1).
The women in the DRC site had the highest prevalence of malaria in early pregnancy (297/469, 63%), followed by the women in the Kenya site (244/642, 38%),
then the Zambia site (21/335, 6%). Half of the women
(n = 724, 50%) were randomized to the LDA (treatment)
arm. Of the women who received LDA, 39% (279/724)
had malaria in early pregnancy, equal to 39% of women
(283/722) with malaria in early pregnancy who were randomized to placebo (Table 1).
Baseline characteristics were similar among women
who received LDA vs placebo, and among women who
had malaria in early pregnancy vs those who did not, in
terms of gestational age at enrollment, maternal height,
weight, body mass index (BMI), antenatal care visits,
delivery attendant, delivery location and mode of delivery (Table 1). Women with malaria in early pregnancy
trended toward younger maternal ages and fewer years of
formal education. The majority of all mothers had deliveries attended by nurses/midwives, delivered in clinics
or health centers and had vaginal deliveries. The median
number of antenatal care (ANC) visits was four.
Preterm birth occurred in 83 women in the LDA group
and 90 women in the placebo group (PR 0.92, 95% CI
0.70, 1.22) (Table 2).
The association between LDA and preterm birth was
similar among the malaria negative (PR 0.89, 95% CI
0.59, 1.36) and the malaria positive group (PR 0.95, 95%
CI 0.66, 1.38, p = 0.75). Perinatal mortality occurred in
41 pregnancies in the LDA group and 43 pregnancies
in the placebo group (PR 0.95, 95% CI 0.63, 1.44). The
association between LDA and perinatal mortality varied
between the malaria negative (PR 0.56, 95% CI 0.31, 1.03)
and the malaria positive group (PR 1.69, 95% CI 0.91,
3.14), as the model indicated interaction between LDA
treatment and malaria infection for perinatal mortality,
(p = 0.014).
Malaria in late pregnancy was present in 92 pregnancies in the LDA group and 83 pregnancies in the placebo
group (PR 1.13, 95% CI 0.88, 1.45) (Table 2). The model
did not show a significant interaction between LDA
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Fig. 1 Study Participants

treatment and early malaria infection on late malaria status (p = 0.15). Outcomes of hypertensive disorders, small
for gestational age, vaginal bleeding, antepartum hemorrhage, postpartum hemorrhage, maternal mortality, and
the combined outcome of preterm and hypertensive disorders occurred infrequently among the groups. The protective effect of LDA on very low birth weight (< 1500 g)
is observed in the malaria negative group but not in the
malaria positive group. No evidence of an interaction
between LDA and malaria status was observed for any
other secondary neonatal outcomes of interest (i.e., interaction terms in model-based analyses were not significant and PRs numerically do not appear to differ).
Preterm birth and perinatal mortality occurred at different frequencies in each research site (Table 3).
In the DRC, 92/469 (20%) pregnancies ended in preterm birth, compared to 58/642 (9%) in Kenya and
23/335 (7%) in Zambia. Perinatal mortality was observed
with an incidence of 7% (32/469) in the DRC, 5% (34/642)
in Kenya, and 5% (18/335) in Zambia. Effect measure
modification was observed in site specific analyses only
for perinatal mortality for DRC (p = 0.035).
We report hemoglobin levels in late pregnancy based
on malaria infection in early pregnancy (Table 4).
Hemoglobin levels in late pregnancy appeared to
be similar among women with malaria positive and

women that were malaria negative, and LDA treated and
untreated groups (Fig. 2).

Discussion
Our study investigated the potential interaction between
LDA and malaria in early pregnancy. We found that
malaria in early pregnancy did not modify the effects
of LDA on the risk of preterm birth. However, we did
observe effect measure modification between LDA and
malaria on perinatal mortality. Women without malaria
in early pregnancy had lower rates of perinatal mortality
when given LDA versus placebo, but this protective effect
was not observed for women with malaria in early pregnancy. Third trimester hemoglobin levels did not vary
based on LDA exposure and malaria status.
Our study adds important knowledge to the lessons
learned from the ASPIRIN trial. Within the ASPIRIN
trial, we observed a risk ratio of 0.89 (0.81 to 0.98) for
preterm birth, among women receiving LDA compared
to women receiving placebo, and an absolute reduction
of prematurity of 2% [3]. While the ASPIRIN trial was
not powered to evaluate a benefit by site, the relative risk
ranged from 0.66 (0.44, 1.00) to 1.13 (0.90, 1.42) across
the 8 sites, with the highest RR being observed in DRC. It
is biologically plausible that the beneficial effect of LDA
on preterm birth was modified by malaria given the role
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Table 1 Baseline characteristics of study population by treatment arm and malaria status in early pregnancy
Variable

ALL CALL COUNTRIES
LDA (N = 724)

Randomized, N (%)

PLACEBO (N = 722)

Malaria negative

Malaria positive

Malaria negative

Malaria positive

445 (61)

279 (39)

439 (61)

283 (39)

Maternal age (years), N (%)
   < 20

225 (50·6)

209 (74·9)

250 (56·9)

206 (72·8)

  20–29

214 (48·1)

69 (24·7)

185 (42·1)

74 (26·1)

   > 29

6 (1·3)

1 (0·4)

4 (0·9)

3 (1·1)

   Median (P25, P75)

19·0 (18·0, 22·0)

18·0 (17·0, 19·5)

19·0 (18·0, 21·0)

18·0 (17·0, 20·0)

Projected gestational age at enrollment (weeks, days), N (%)
6, 0 – 7, 6

63 (14·2)

30 (10·8)

72 (16·4)

26 (9·2)

8, 0 – 9, 6

134 (30·1)

75 (26·9)

114 (26·0)

76 (26·9)

10, 0 – 10, 6

66 (14·8)

33 (11·8)

57 (13·0)

31 (11·0)

11, 0 – 11,6

47 (10·6)

48 (17·2)

66 (15·0)

54 (19·1)

12, 0 – 13, 6

135 (30·3)

93 (33·3)

130 (29·6)

96 (33·9)

Median (P25, P75)

10·3 (8·7, 12·3)

11·0 (9·1, 12·4)

10·6 (8·4, 12·1)

11·1 (9·0, 12·4)

Maternal education, N (%)
No formal

20 (4·5)

25 (9·0)

19 (4·3)

24 (8·5)

Primary

58 (13·0)

84 (30·1)

60 (13·7)

97 (34·3)

Secondary

334 (75·1)

158 (56·6)

327 (74·5)

156 (55·1)

University +

33 (7·4)

12 (4·3)

33 (7·5)

6 (2·1)

Maternal height (cm), N
Mean (StdDev)

157·0 (7·5)

155·6 (8·0)

157·0 (7·4)

155·2 (7·9)

Median (P25, P75)

158·0 (152·5, 162·0)

156·0 (150·2, 161·0)

157·0 (152·5, 161·9)

155·0 (150·0, 160·0)

Maternal weight (kg), N
Mean (StdDev)

55·0 (8·1)

53·0 (7·4)

55·0 (8·3)

52·3 (7·5)

Median (P25, P75)

54·0 (50·0, 59·0)

52·2 (48·0, 58·0)

54·0 (50·0, 60·0)

52·0 (47·0, 56·8)

Maternal BMI (kg/m2), N
Mean (StdDev)

22·4 (3·4)

22·0 (3·1)

22·3 (3·4)

21·8 (3·1)

Median (P25, P75)

21·1 (20·0, 24·0)

21·7 (19·7, 23·4)

21·9 (20·0, 24·1)

21.5 (19·5, 23·3)

Mean (StdDev)

4·2 (1·1)

3·9 (1·3)

4·2 (1·1)

3·9 (1·2)

Median (P25, P75)

4·0 (4·0, 5·0)

4·0 (3·0, 5·0)

4·0 (4·0, 5·0)

4·0 (3·0, 5·0)

Antenatal care visits, N

Delivery attendant, N (%)
Physician

24 (5·4)

9 (3·2)

18 (4·1)

9 (3·2)

Nurse/nurse midwife

391 (87·9)

241 (86·4)

383 (87·2)

239 (84·5)

Traditional birth attendant

19 (4·3)

22 (7·9)

23 (5·2)

30 (10·6)

Family/Self/Other

11 (2·5)

7 (2·5)

15 (3·4)

5 (1·8)

Delivery location, N (%)
Hospital

113 (25·4)

58 (20·8)

122 (27·8)

46 (16·3)

Clinic/health center

296 (66·5)

180 (64·5)

270 (61·5)

194 (68·6)

Home/Other

36 (8·1)

41 (14·7)

47 (10·7)

43 (15·2)

Delivery mode, N (%)
Vaginal

426 (95·7)

271 (97·1)

422 (96·1)

276 (97·5)

C-section

19 (4·3)

8 (2·9)

17 (3·9)

7 (2·5)

Site, N (%)
DRC

87 (19·6)

140 (50·2)

85 (19·4)

157 (55·5)

Kenya

199 (44·7)

130 (46·6)

199 (45·3)

114 (40·3)

Zambia

159 (35·7)

9 (3·2)

155 (35·3)

12 (4·2)
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Table 2 Primary and secondary efficacy outcomes based on infection with malaria in early pregnancy
Variable

Overall
n/N (%)

PR (95% CI)

Malaria Negative

Malaria Positive

Aspirin – Malaria
Interaction p-value

n/N (%)

PR (95% CI)

n/N (%)

PR (95% CI)

38/445 (9)

0·89 (0·59, 1·36)

45/279 (16)

0·95 (0·66, 1·38)

0.75

5·07 (0·24, 105·17)

–

0·97 (0·61, 1·54)

0.62

1·69 (0·91, 3·14)

0.014

0·51 (0·05, 5·56)

0.64

1·01 (0·02, 50·76)

–

2·03 (0·37, 10·99)

–

1·01 (0·02, 50·94)

–

3·04 (0·12, 74·38)

–

1·09 (0·53, 2·21)

0.40

0·98 (0·65, 1·47)

0.69

2·67 (0·71, 9·95)

0.007

0·87 (0·30, 2·55)

0.99

0·94 (0·70, 1·26)

0.15

Primary Outcome
Preterm delivery
  Aspirin

83/724 (11)

  Placebo

90/722 (12)

0·92 (0·70, 1·22)

42/439 (10)

48/283 (17)

Hypertensive disorders
Aspirin

10/724 (1)

Placebo

9/722 (1)

1·11 (0·45, 2·71)

8/445 (2)

0·88 (0·34, 2·25)

9/439 (2)

2/279 (1)
0/283 (0)

Small for gestational age
Aspirin

89/686 (13)

Placebo

78/668 (12)

1·11 (0·84, 1·48)

58/421 (14)

1·21 (0·84, 1·73)

46/403 (11)

31/265 (12)
32/265 (12)

Perinatal mortality
Aspirin

41/724 (6)

Placebo

43/722 (6)

0·95 (0·63, 1·44)

16/445 (4)

0·56 (0·31, 1·03)

28/439 (6)

25/279 (9)
15/283 (5)

Other Maternal Outcomes of Interest
Vaginal bleeding
  Aspirin

12/713 (2)

  Placebo

14/715 (2)

0·86 (0·40, 1·85)

11/437 (3)

0·91 (0·41, 2·05)

12/435 (3)

1/276 (0)
2/280 (1)

Antepartum hemorrhage
Aspirin

4/721 (1)

Placebo

0/717 (0)

8·95 (0·48, 165·94)

4/442 (1)

8·86 (0·48, 164·04)

0/435 (0)

0/279 (0)
0/282 (0)

Postpartum hemorrhage
Aspirin

6/724 (1)

Placebo

2/722 (0)

2·99 (0·61, 14·77)

2/445 (0)

4·93 (0·24, 102·46)

0/439 (0)

4/279 (1)
2/283 (0)

Maternal mortality through 42 days
Aspirin

0/724 (0)

Placebo

1/722 (0)

0·33 (0·02, 8·15)

0/445 (0)

0·33 (0·02, 8·05)

1/439 (0)

0/279 (0)
0/283 (0)

Preterm and hypertensive disorders
Aspirin

1/724 (0)

Placebo

0/722 (0)

2·99 (0·12, 73·32)

0/445 (0)

0·99 (0·02, 49·61)

0/439 (0)

1/279 (0)
0/283 (0)

Other Fetal Outcomes of Interest
Preterm < 34 weeks of pregnancy
  Aspirin

30/724 (4)

  Placebo

34/722 (5)

0·88 (0·54, 1·42)

15/445 (3)

0·74 (0·38, 1·43)

20/439 (5)

15/279 (5)
14/283 (5)

Birth weight < 2500 g
Aspirin

76/715(11)

Placebo

80/708 (11)

0·94 (0·70, 1·27)

37/439 (8)

0·91 (0·59, 1·39)

40/432 (9)

39/276 (14)
40/276 (15)

Birth weight < 1500 g
Aspirin

9/715 (1)

Placebo

13/708 (2)

0·69 (0·29, 1·59)

1/439 (0)

0·10 (0·01, 0·77)

10/432 (2)

8/276 (3)
3/276 (1)

Stillbirth
Aspirin

14/718 (2)

Placebo

16/712 (2)

0·87 (0·43, 1·76)

8/442 (2)

0·87 (0·34, 2·23)

9/432 (2)

6/276 (2)
7/280 (3)

Malaria in late pregnancy (26–30 weeks)
Aspirin

92/296 (31)

Placebo

83/301 (28)

1·13 (0·88, 1·45)

42/177 (24)
31/185 (17)

1·42 (0·93, 2·15)

50/119 (42)
52/116 (45)
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Table 3 Preterm birth and perinatal mortality outcomes, by site
Outcome

Overall
n/N (%)

Malaria Negative

Malaria positive

PR (95% CI)

N w/o outcome

PR (95% CI)

N w/o outcome

PR (95% CI)

Aspirin – Malaria
Interaction
p-value

0·98 (0·68, 1·41)

14/87 (16)

1·05 (0·53, 2·10)

30/140 (21)

0·96 (0·62, 1·48)

0.84

2·40 (1·01, 5·72)

0.035

0·94 (0·46, 1·92)

0.99

1·10 (0·45, 2·68)

0.62

–

–

–

1.00

DRC DRC
Preterm Delivery
  Aspirin

44/227 (19)

  Placebo

48/242 (20)

13/85 (15)

35/157 (22)

Perinatal Mortality
Aspirin

18/227 (8)

Placebo

14/242 (6)

1·37 (0·70, 2·69)

3/87 (3)

0·42 (0·11, 1·57)

7/85 (8)

15/140 (11)
7/157 (4)

Kenya
Preterm Delivery
  Aspirin

29/329 (9)

  Placebo

29/313 (9)

0·95 (0·58, 1·55)

15/199 (8)

0·94 (0·48, 1·84)

16/199 (8)

14/130 (11)
13/114 (11)

Perinatal Mortality
Aspirin

17/329 (5)

Placebo

17/313 (5)

0·95 (0·49, 1·83)

7/199 (4)

0·78 (0·30, 2·05)

9/199 (5)

10/130 (8)
8/114 (7)

Zambia
Preterm Delivery
Aspirin

10/168 (6)

Placebo

13/167 (8)

0·76 (0·34, 1·70)

9/159 (6)

0·67 (0·30, 1·53)

13/155 (8)

1/9 (11)
0/12 (0)

Perinatal Mortality
Aspirin

6/168 (4)

Placebo

12/167 (7)

0·50 (0·19, 1·29)

6/159 (4)

0·49 (0·19, 1·27)

12/155 (8)

0/9 (0)
0/12 (0)

Notes: PR is prevalence ratio
PR was not calculated for cells in which no participants experienced the outcome

Table 4 Hemoglobin level, by malaria infection and aspirin exposure
Hemoglobin cutpoint

Overall

Malaria Negative

Malaria positive

N (w/ and w/o
outcome)

PR (95% CI)

N (w/ and w/o
outcome)

PR (95% CI)

N (w/ and w/o
outcome)

PR (95% CI)

Aspirin

11/618

0·91 (0·04, 2·04)

3/376

0·58 (0·14, 2·43)

8/242

1·16 (0·43, 3·14)

Placebo

12/610

Hemoglobin ≤ 8 g/dL

Hemoglobin ≤ 9 g/dL
Aspirin

43/586

Placebo

42/580

Hemoglobin ≤ 10 g/dL
Aspirin

122/507

Placebo

120/502

Hemoglobin ≤ 11 g/dL
Aspirin

266/363

Placebo

256/366

5/364
1·06 (0·70, 1·58)

10/369

7/246
0·57 (0·27, 1·23)

17/352
1·01 (0·80, 1·26)

49/330

128/251
117/252

1·34 (0·82, 2·18)

25/228
1·04 (0·71, 1·51)

46/323
1·03 (0·90, 1·17)

33/217

73/177

1·00 (0·76, 1·31)

74/179
1·07 (0·87, 1·31)

138/112

1·00 (0·86, 1·18)

139/114

Note: Hemoglobin measured between 26–30 weeks. Malaria in early pregnancy measured between 6–13 6/7 weeks gestation

of LDA and malaria on placental development [5]. However, our findings did not suggest effect modification on
preterm birth by malaria status.

The ASPIRIN trial reported a trend toward significance in regards to a reduction in perinatal mortality (RR 0.86 [0.75, 1.00]). We report potential effect
measure modification by malaria for the effect of LDA
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Fig. 2 Hemoglobin level in late pregnancy (weeks 26–30), by malaria status in early pregnancy and aspirin exposure

on perinatal mortality, in which women with malaria
in pregnancy might not benefit from LDA. This finding was consistent in the DRC in site-specific analyses.
It does not appear that effect measure modification
through preterm birth explains the perinatal mortality
findings. Our convenience sampling strategy resulted
in a sample too small to fully explore the effect measure modification. Furthermore, because we restricted
our analyses to pregnancies that extended beyond
20 weeks, we might have underestimated the early
effects of malaria and LDA on early pregnancy loss (i.e.,
prior to the gestation of enrollment in the trial).
Treatment or prevention of malaria in pregnancy is
a strategy to improve maternal and neonatal outcomes
[5, 13]. Malaria in pregnancy can exert multiple negative health effects on the mother and the fetus, such as
preterm birth, IUGR, and stillbirth [5]. Malaria in pregnancy has also been associated with hypertensive disorders of pregnancy, a condition that might be prevented
by LDA treatment in pregnancy [14]. Our cohort had
a low incidence of hypertensive disorders of pregnancy
(1.4% in the LDA group and 1.2% in the placebo group),
an incidence that is lower than predicted. Therefore,
the joint effects of malaria and LDA on pregnancy outcomes among hypertensive women are still not known.
This study has several strengths. Because of the
design of the ASPIRIN trial, we were able to diagnose
malaria in early pregnancy, at a median gestational age

of 10 weeks. We were also able to study women in three
countries with differing levels of malaria endemicity.
Despite these strengths, our findings and inferences
are limited by some key features of our study design. In
our cohort we did not observe an effect of LDA on the
outcome of preterm birth. This differed from the overall
findings of the ASPIRIN trial, which did show a positive
association between LDA and reduction of preterm birth.
Because of our limited sample size, we could have underestimated the contribution of malaria to preterm birth
and the beneficial effects of LDA. We are also limited
in our ability to describe malaria in various pathological stages (incubation, chill, fever, and sweating periods),
and therefore can not correlate pregnancy outcomes
based on stage of protozoal infection in the first trimester of pregnancy. We also did not have robust information about malaria treatment during pregnancy and are
limited in our conclusions regarding anti-malarial treatment effects. Our analysis population is restricted to
pregnancy outcomes > 20 weeks based on the primary
outcome of the ASPIRIN trial. This restriction limits our
ability to determine the effects of malaria and aspirin on
early pregnancy loss.
Our study emphasizes the importance of evaluating
public health interventions within the context in which
they will be used, particularly in LMICs where disease
burden from infectious diseases is high. Endemic diseases might modify the effect of treatment strategies, by
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potentiating or eliminating the desired effect. Treatment
strategies could be less effective, if not implemented
in conjunction with other public health interventions
[15, 16]. This is particularly true for pre-pregnancy and
pregnancy interventions in which packages of interventions are suggested [17]. Since there is an urgent need
for timely interventions to improve maternal and newborn health, studies should investigate interventions in
diverse settings, where disease endemicity varies, or in
conjunction with treatment for concurrent diseases such
as malaria.

Conclusion
Malaria infections during pregnancy are an important
cause of preterm birth in many LMICs, especially subSaharan African countries where malaria infection in
pregnancy is common. Recent trials demonstrate that
low dose aspirin (LDA) is an effective strategy to reduce
preterm birth, however it is not known if the effect of
LDA will be modified based on regional differences in
the etiology of preterm birth in low and middle income
countries (LMICs). Our study investigated the potential interaction between LDA and malaria in early pregnancy. We found that malaria in early pregnancy did not
modify the effects of LDA on the risk of preterm birth.
However, malaria modified the benefit of LDA on perinatal mortality, and was associated with less efficacy of
LDA to reduce this outcome. Given the urgent need for
timely interventions to improve maternal and newborn
health, our study highlights the importance of conducting intervention studies in diverse settings, where disease
endemicity varies, or in conjunction with treatment for
concurrent diseases such as malaria.
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